{"id":"visudyne-for-injection","safety":{"commonSideEffects":[{"rate":"7-12","effect":"Injection site reactions (pain, edema, extravasation)"},{"rate":"1-3","effect":"Photosensitivity reactions"},{"rate":"5-10","effect":"Vision decrease or blurred vision"},{"rate":"2-5","effect":"Headache"},{"rate":"2-5","effect":"Subretinal or retinal hemorrhage"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Verteporfin is a benzoporphyrin derivative that preferentially localizes to neovascular tissue. Upon intravenous injection, it circulates and concentrates in abnormal choroidal neovascular membranes. When exposed to non-thermal red light (689 nm wavelength) in a process called photodynamic therapy (PDT), verteporfin generates singlet oxygen and reactive oxygen species that cause selective thrombosis and closure of the abnormal vessels while minimizing damage to surrounding normal tissue.","oneSentence":"Visudyne (verteporfin) is a photosensitizing agent that accumulates in abnormal blood vessels and is activated by light to produce reactive oxygen species that destroy those vessels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:51.040Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Age-related macular degeneration with predominantly classic choroidal neovascularization"},{"name":"Pathologic myopia with choroidal neovascularization"},{"name":"Polypoidal choroidal vasculopathy"}]},"trialDetails":[{"nctId":"NCT07488988","phase":"PHASE2","title":"SCARFREE-001: Verteporfin for Scar Prevention","status":"NOT_YET_RECRUITING","sponsor":"Odense University Hospital","startDate":"2026-06","conditions":"Surgical Scar","enrollment":12},{"nctId":"NCT06807359","phase":"PHASE1, PHASE2","title":"Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System","status":"RECRUITING","sponsor":"SpectraCure AB","startDate":"2025-01-06","conditions":"Prostate Cancer","enrollment":43},{"nctId":"NCT00527475","phase":"PHASE2","title":"Ranibizumab and Reduced Fluence PDT for AMD","status":"COMPLETED","sponsor":"Texas Retina Associates","startDate":"2007-05","conditions":"Macular Degeneration","enrollment":60},{"nctId":"NCT03941587","phase":"NA","title":"Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment","status":"COMPLETED","sponsor":"Singapore National Eye Centre","startDate":"2021-02-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":60},{"nctId":"NCT03067051","phase":"PHASE1, PHASE2","title":"Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System","status":"RECRUITING","sponsor":"SpectraCure AB","startDate":"2017-03-21","conditions":"Recurrent Prostate Cancer","enrollment":66},{"nctId":"NCT04075136","phase":"PHASE4","title":"Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-30","conditions":"Exudative Age Related Macular Degeneration","enrollment":""},{"nctId":"NCT02120950","phase":"PHASE4","title":"Aflibercept in Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-05-29","conditions":"Neovascular Macular Degeneration","enrollment":333},{"nctId":"NCT04075188","phase":"NA","title":"Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo","startDate":"2017-09-18","conditions":"Choroidal Neovascularization, Choroid Disease","enrollment":17},{"nctId":"NCT01922102","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09-11","conditions":"Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)","enrollment":457},{"nctId":"NCT02457026","phase":"NA","title":"Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2016-01","conditions":"Neovascular Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT01482910","phase":"PHASE3","title":"VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12","conditions":"Macular Degeneration","enrollment":304},{"nctId":"NCT01032109","phase":"NA","title":"Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Kumamoto University","startDate":"2006-10","conditions":"Age-related Macular Degeneration","enrollment":45},{"nctId":"NCT01666236","phase":"PHASE4","title":"Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy","status":"WITHDRAWN","sponsor":"Federal University of São Paulo","startDate":"2012-09","conditions":"Choroidal Neovascularization, Retinal Pigment Epithelial Detachment","enrollment":""},{"nctId":"NCT01217944","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-10","conditions":"Pathological Myopia","enrollment":277},{"nctId":"NCT01256580","phase":"NA","title":"Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD","status":"WITHDRAWN","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2010-08","conditions":"Choroidal Neovascularization, Myopia, Punctate Inner Choroidopathy (PIC)","enrollment":""},{"nctId":"NCT01968486","phase":"PHASE1","title":"Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2012-06","conditions":"Myopia, Degenerative","enrollment":60},{"nctId":"NCT01325181","phase":"PHASE1, PHASE2","title":"Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy","status":"COMPLETED","sponsor":"Jang Won Heo","startDate":"2009-07","conditions":"Chronic Central Serous Chorioretinopathy","enrollment":34},{"nctId":"NCT00211419","phase":"PHASE1","title":"Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"","conditions":"Maculopathy, Age-Related","enrollment":""},{"nctId":"NCT00726973","phase":"NA","title":"Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)","status":"WITHDRAWN","sponsor":"Lahey Clinic","startDate":"2006-12","conditions":"Macular Edema","enrollment":""},{"nctId":"NCT00492284","phase":"PHASE2","title":"Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)","status":"COMPLETED","sponsor":"QLT Inc.","startDate":"2007-07","conditions":"Choroidal Neovascularization, Macular Degeneration","enrollment":162},{"nctId":"NCT00433017","phase":"PHASE2, PHASE3","title":"Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-05","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":255},{"nctId":"NCT00436553","phase":"PHASE3","title":"Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":321},{"nctId":"NCT00049959","phase":"PHASE3","title":"Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.","status":"TERMINATED","sponsor":"QLT Inc.","startDate":"","conditions":"Basal Cell Carcinoma, Nevoid Basal Cell Carcinoma Syndrome, Gorlin Syndrome","enrollment":""},{"nctId":"NCT00546936","phase":"PHASE2","title":"Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis","status":"UNKNOWN","sponsor":"Barnes Retina Institute","startDate":"2007-10","conditions":"Presumed Ocular Histoplasmosis (POHS)","enrollment":30},{"nctId":"NCT00813891","phase":"PHASE4","title":"Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2009-01","conditions":"Macular Degeneration, Visual Acuity","enrollment":180},{"nctId":"NCT00134667","phase":"PHASE4","title":"Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Eyetech Pharmaceuticals","startDate":"2005-03","conditions":"Age-Related Macular Degeneration","enrollment":360},{"nctId":"NCT00135837","phase":"PHASE4","title":"Photodynamic Therapy in Occult-Only Lesions (POOL)","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-06","conditions":"Age-Related Macular Degeneration","enrollment":202},{"nctId":"NCT00121407","phase":"PHASE3","title":"Visudyne® in Occult (VIO)","status":"COMPLETED","sponsor":"QLT Inc.","startDate":"2002-03","conditions":"Macular Degeneration","enrollment":364}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Visudyne for injection","genericName":"Visudyne for injection","companyName":"QLT Inc.","companyId":"qlt-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Visudyne (verteporfin) is a photosensitizing agent that accumulates in abnormal blood vessels and is activated by light to produce reactive oxygen species that destroy those vessels. Used for Age-related macular degeneration with predominantly classic choroidal neovascularization, Pathologic myopia with choroidal neovascularization, Polypoidal choroidal vasculopathy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}